Roche presents pivotal First Phase III cancer immunotherapy Tecentriq in combination with Avastin to show an improvement in liver cancer patients

Nov 22,2019: Roche presents positive results from the Phase III IMbrave150 study evaluating Tecentriq^® (atezolizumab) in combination with Avastin^® (bevacizumab) for the treatment  of loiver cancer.

As compared with sorafenib results shows that Tecentriq in combination with Avastin reduced the risk of death (OS) by 42% hazard ratio and reduced the risk of disease worsening or death (PFS) by 41%.

Every year, more that 750,000 individuals worldwide are diagnosed with HCC, the most common form of liver cancer and this is increasing day by day.                                                                                   https://www.roche.com/media/releases/med-cor-2019-11-22b.htm